CompanyGraph
What stands out
- Pays more per share than it earned over the last twelve months
At a glance
- Depends onMidstream position: 5 outgoing, 6 incoming connections
- ScaleRevenue is $1.3B, above the global median of $520.53M
- PositionGross margin is 35.4%, higher than 95% of its Pharmaceutical Retailers peers (median 24.3%)
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
What stands out
- Pays more per share than it earned over the last twelve months
Dividends view
Yield
7.67%Above 5Y avg (4.00%)
Annual Rate
CNY 1.27Paid annual
Payout Ratio
107.8%High
Payback Period
13.0 yr
Last Ex-Dividend
Jun 12, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.61BCNY388.40M · vs all stocks (USD)
Trailing P/E
16.57xvs Pharmaceutical Retailers peers
Revenue (TTM)
8.72BCNY1.30B · vs all stocks (USD)
Profit Margin
1.73%vs Pharmaceutical Retailers peers
Beta
0.5300xvs all stocks
52-Week Change
-23.55%vs all stocks
Market Capitalization
2.61BCNY388.40M · vs all stocks (USD)
Enterprise Value
5.95BCNY884.88M · vs all stocks (USD)
Trailing P/E
16.57xvs Pharmaceutical Retailers peers
PEG Ratio
1.82xPrice to Sales (TTM)
0.2996xvs Pharmaceutical Retailers peers
Price to Book (MRQ)
0.9244xvs Pharmaceutical Retailers peers
Enterprise to Revenue
0.6830xvs Pharmaceutical Retailers peers
Enterprise to EBITDA
13.65xvs Pharmaceutical Retailers peers
Gross Margin
35.45%vs Pharmaceutical Retailers peers
Profit Margin
1.73%vs Pharmaceutical Retailers peers
Operating Margin
3.34%vs Pharmaceutical Retailers peers
Return on Assets (TTM)
2.34%vs Pharmaceutical Retailers peers
Return on Equity (TTM)
5.54%vs Pharmaceutical Retailers peers
Revenue (TTM)
8.72BCNY1.30B · vs all stocks (USD)
Revenue per Share (TTM)
59.10CNYUpdated Aug 21, 2026Quarterly Revenue Growth
-8.90%vs Pharmaceutical Retailers peers
Gross Profit (TTM)
3.13BCNY465.97M · vs all stocks (USD)
EBITDA (TTM)
1.22BCNY181.29M · vs all stocks (USD)
Net Income (TTM)
150.57MCNY22.39M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
7.20%vs Pharmaceutical Retailers peers
Operating Cash Flow (TTM)
1.15BCNY171.30M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
860.64MCNY127.99M · vs all stocks (USD)
Trailing Annual Dividend Rate
1.27CNYUpdated Aug 21, 2026Trailing Annual Dividend Yield
7.67%vs all stocks
5-Year Average Dividend Yield
4.00%vs all stocks
Payout Ratio
107.84%vs Pharmaceutical Retailers peers
Minority Interest (Equity)
-1.31MCNYFY2025 · Dec 31, 2025Revenue
8.92BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
5.70BCNYFY2025 · Dec 31, 2025Gross Profit
3.22BCNYFY2025 · Dec 31, 2025Operating Income
425.65MCNY63.30M · vs all stocks (USD)
Pre-tax Income
207.16MCNYFY2025 · Dec 31, 2025Income Tax Expense
59.04MCNYFY2025 · Dec 31, 2025Net Income
148.12MCNYFY2025 · Dec 31, 2025EBIT
327.88MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
1.22BCNYFY2025 · Dec 31, 2025Selling, General & Administrative
658.39MCNYFY2025 · Dec 31, 2025Other Operating Expenses
38.76MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
3.36MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
120.72MCNYFY2025 · Dec 31, 2025EPS (Basic)
1.00CNYFY2025 · Dec 31, 2025EPS (Diluted)
1.00CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
148.15MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
148.15MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
148.12MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
33.44KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
786.15MCNYFY2025 · Dec 31, 2025Free Cash Flow
665.74MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
301.87MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
148.12MCNYFY2025 · Dec 31, 2025Other Non-cash Items
283.00MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-623.75MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
978.78MCNYFY2025 · Dec 31, 2025Capital Expenditures
-120.40MCNYFY2025 · Dec 31, 2025Purchase of Investments
-51.39MCNYFY2025 · Dec 31, 2025Sale of Investments
100.50MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-71.29MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
1.32BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-1.29BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-242.90MCNYFY2025 · Dec 31, 2025Other Financing Charges
-784.14MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-997.31MCNYFY2025 · Dec 31, 2025Shares Outstanding
154.54MSharesUpdated Aug 21, 2026Float Shares
66.84MSharesUpdated Aug 21, 2026% Held by Insiders
54.43%vs all stocks
% Held by Institutions
4.47%vs all stocks
Total Cash (MRQ)
692.69MCNY103.01M · vs all stocks (USD)
Total Cash per Share (MRQ)
4.67CNYUpdated Aug 21, 2026Total Debt (MRQ)
4.20BCNY624.55M · vs all stocks (USD)
Total Debt to Equity (MRQ)
1.55xvs Pharmaceutical Retailers peers
Current Ratio (MRQ)
0.7840xvs Pharmaceutical Retailers peers
Book Value per Share (MRQ)
18.28CNYUpdated Aug 21, 2026Total Assets
9.75BCNY1.45B · vs all stocks (USD)
Total Current Assets
4.33BCNYFY2025 · Dec 31, 2025Total Liabilities
7.08BCNYFY2025 · Dec 31, 2025Total Non-current Assets
5.42BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
1.70BCNYFY2025 · Dec 31, 2025Total Current Liabilities
5.38BCNYFY2025 · Dec 31, 2025Cash
275.03MCNYFY2025 · Dec 31, 2025Cash Equivalents
603.55MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
878.58MCNYFY2025 · Dec 31, 2025Accounts Receivable
1.06BCNYFY2025 · Dec 31, 2025Inventory
2.11BCNYFY2025 · Dec 31, 2025Accounts Payable
2.25BCNYFY2025 · Dec 31, 2025Short-term Debt
2.80BCNYFY2025 · Dec 31, 2025Other Current Liabilities
2.33MCNYFY2025 · Dec 31, 2025Long-term Debt
1.48BCNYFY2025 · Dec 31, 2025Common Stock (Book)
154.54MCNYFY2025 · Dec 31, 2025Retained Earnings
1.17BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.67BCNY397.30M · vs all stocks (USD)
Treasury Stock
145.44MCNYFY2025 · Dec 31, 202552-Week Low
14.41CNYUpdated Aug 21, 202652-Week High
22.30CNYUpdated Aug 21, 202652-Week Change
-23.55%vs all stocks
Beta
0.5300xvs all stocks
50-Day MA
16.23CNYUpdated Aug 21, 2026200-Day MA
18.86CNYUpdated Aug 21, 2026Avg 10-Day Volume
2.53MSharesUpdated Aug 21, 2026Avg 30-Day Volume
2.14MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
1.02CNYUpdated Aug 21, 20264 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Diagnostic
Elevated ROE With High Debt-to-Equity and Equity Multiplier
Return on equity reads high on a balance sheet carrying a lot of debt against that equity.
Reads
How is this stock valued?
Close Below 40W SMA With Profitability
The price sits below its 40-week average, on three profitable years and cash above profit.
Reads
Where is this company structurally exposed?
Within or Near the Altman Distress Zone
Debt is a large share of its assets, and large against its cash flow.
Reads
Elevated Leverage on Three Denominators
Debt sits high against its equity, its assets, and its cash flow.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 35.4%, higher than 95% of its Pharmaceutical Retailers peers (median 24.3%)Significant
Gross margin: 0.35Industry median: 0.24Industry P95: 0.34Peers compared: 22.00
Structural Tensions
Pays more per share than it earned over the last twelve monthsSignificant
Payout Ratio: 1.08Dividend per Share: 1.27Earnings per Share: 1.02
Financial Health
Altman Z-Score 1.28: grey zoneSignificant
Altman Z-Score: 1.28
Supply Chain
Midstream position: 5 outgoing, 6 incoming connectionsNotable
Outgoing: 5.00Incoming: 6.00
High connectivity hub: 11 industry connectionsNotable
Total Connections: 11.00
Scale
Revenue is $1.3B, above the global median of $520.53MNotable
Revenue (USD): 1,296,395,933Global Median: 520,528,949.311
Levered free cash flow is $127.99M, above the global median of $16.24MNotable
Levered free cash flow (USD): 127,985,165.284Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Beijing Hanbang Technology Co., Ltd.
Tier 1FlowUnit ReplicationProductionRule
Camping World Holdings Inc.
Tier 1FlowUnit ReplicationInterfaceRisk
G-7 Holdings Inc.
Tier 1FlowUnit ReplicationInterfaceProduction
Shoe Carnival Inc.
Tier 1FlowUnit ReplicationRiskInterface
Sichuan Hezong Medicine Co., Ltd.
Tier 1FlowUnit ReplicationProductionInterface
Ministop Co., Ltd.
Tier 1FlowUnit ReplicationInterfaceProduction
OceanPact Servicos Maritimos S.A.
Tier 1FlowUnit ReplicationProductionRule
Chongqing Mas Sci & Technology Co., Ltd.
Tier 1FlowUnit ReplicationProductionRule
Caleres Inc.
Tier 1FlowUnit ReplicationRiskInterface
Kits Eyecare Ltd.
Tier 1FlowUnit ReplicationProductionInterface
Companies that share active interpretations — structural patterns currently present in both stocks.
Verra Mobility Corporation
4 interpretationsWithin or Near the Altman Distress ZoneClose Below 40W SMA With ProfitabilityElevated ROE With High Debt-to-Equity and Equity MultiplierElevated Leverage on Three Denominators
Arko Petroleum Corp.
3 interpretationsClose Below 40W SMA With ProfitabilityElevated ROE With High Debt-to-Equity and Equity MultiplierElevated Leverage on Three Denominators
Charter Communications Inc
4 interpretationsWithin or Near the Altman Distress ZoneClose Below 40W SMA With ProfitabilityElevated ROE With High Debt-to-Equity and Equity MultiplierElevated Leverage on Three Denominators